Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Hologic stock in Canada | $73.61
Own Hologic shares in just a few minutes.
Hologic Inc is a medical instruments & supplies business based in the US. Hologic shares (HOLX) are listed on the NASDAQ and all prices are listed in US Dollars. Hologic employs 5,814 staff and has a trailing 12-month revenue of around USD$5.7 billion.
How to buy shares in Hologic
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – HOLX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Is it a good time to buy Hologic stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
What's in this guide?
- Can I buy shares in Hologic?
- Has coronavirus impacted Hologic shares?
- Hologic shares summary
- Compare share dealing platforms
- Is Hologic stock a buy or sell?
- Hologic performance over time
- Can I short Hologic shares?
- Is Hologic suitable for ethical investing?
- Are Hologic shares over-valued?
- Hologic's financials
- How volatile are Hologic shares?
- Does Hologic pay a dividend?
- Have Hologic shares ever split?
- Other common questions
How has Coronavirus impacted Hologic's stock price?
Since the stock market crash in March caused by coronavirus, Hologic's stock price has had significant positive movement.
Its last market close was $73.61, which is 28.56% up on its pre-crash value of $52.59 and 177.88% up on the lowest point reached during the March crash when the stocks fell as low as $26.49.
If you had bought $1,000 worth of Hologic stocks at the start of February 2020, those stocks would have been worth $547.94 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,372.83.
Hologic stock priceUse our graph to track the performance of HOLX stocks over time.
Hologic shares at a glance
|Latest market close||$73.61|
|52-week range||$60.10 - $85.00|
|50-day moving average||$75.53|
|200-day moving average||$70.98|
|Wall St. target price||$85.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$7.81|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Hologic price performance over time
|1 week (2021-10-12)||N/A|
|1 month (2021-09-20)||-4.07%|
|3 months (2021-07-23)||1.81%|
|6 months (2021-04-23)||0.34%|
|1 year (2020-10-23)||8.39%|
|2 years (2019-10-23)||53.39%|
|3 years (2018-10-23)||83.11%|
|5 years (2016-10-21)||93.30%|
Is Hologic under- or over-valued?
Valuing Hologic stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Hologic's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Hologic's P/E ratio
Hologic's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, Hologic shares trade at around 9x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Hologic's PEG ratio
Hologic's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.7026. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Hologic's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Hologic's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.1 billion.
The EBITDA is a measure of a Hologic's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$5.7 billion|
|Operating margin TTM||47.49%|
|Gross profit TTM||$2.5 billion|
|Return on assets TTM||21.84%|
|Return on equity TTM||66.32%|
|Market capitalisation||$17.7 billion|
TTM: trailing 12 months
Shorting Hologic shares
There are currently 3.9 million Hologic shares held short by investors – that's known as Hologic's "short interest". This figure is 21% down from 5.0 million last month.
There are a few different ways that this level of interest in shorting Hologic shares can be evaluated.
Hologic's "short interest ratio" (SIR)
Hologic's "short interest ratio" (SIR) is the quantity of Hologic shares currently shorted divided by the average quantity of Hologic shares traded daily (recently around 1.4 million). Hologic's SIR currently stands at 2.71. In other words for every 100,000 Hologic shares traded daily on the market, roughly 2710 shares are currently held short.
However Hologic's short interest can also be evaluated against the total number of Hologic shares, or, against the total number of tradable Hologic shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Hologic's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Hologic shares in existence, roughly 20 shares are currently held short) or 0.0156% of the tradable shares (for every 100,000 tradable Hologic shares, roughly 16 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Hologic.
Hologic's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Hologic.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Hologic's total ESG risk score
Total ESG risk: 28.6
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Hologic's overall score of 28.6 (as at 01/01/2019) is nothing to write home about – landing it in it in the 58th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Hologic is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Hologic's environmental score
Environmental score: 2.95/100
Hologic's environmental score of 2.95 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Hologic is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Hologic's social score
Social score: 11.28/100
Hologic's social score of 11.28 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Hologic is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Hologic's governance score
Governance score: 8.88/100
Hologic's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Hologic is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Hologic's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Hologic scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Hologic has, for the most part, managed to keep its nose clean.
Hologic share dividends
We're not expecting Hologic to pay a dividend over the next 12 months.
Have Hologic's shares ever split?
Hologic's shares were split on a 2:1 basis on 3 April 2008. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Hologic shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Hologic shares which in turn could have impacted Hologic's share price.
Hologic share price volatility
Over the last 12 months, Hologic's shares have ranged in value from as little as $60.1 up to $85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Hologic's is 1.1794. This would suggest that Hologic's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima quantitative viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures.
Stocks similar to Hologic
Frequently asked questions
Hologic in the news
Is Hologic, Inc.'s (NASDAQ:HOLX) Recent Performance Tethered To Its Attractive Financial Prospects?
Hologic Inc. stock outperforms competitors on strong trading day
If You Like EPS Growth Then Check Out Hologic (NASDAQ:HOLX) Before It's Too Late
More on investing
Stock trading doesn’t have to be expensive. Using Finder’s proprietary algorithm, we’ve identified the best cheap Canadian and US stocks to buy now.Read more…
Steps to owning and managing Cue Health stocks, with 24-hour and historical pricing before you buy.Read more…
Steps to owning and managing ARBK stock, with 24-hour and historical pricing before you buy.Read more…
More guides on Finder
How to buy AirSculpt Technologies (AIRS) stock in Canada when it goes public
Everything we know about the AirSculpt Technologies IPO, plus information on how to buy in.
How to buy Candela Medical (CDLA) stock in Canada when it goes public
Everything we know about the Candela Medical IPO, plus information on how to buy in.
How to buy Ensemble Health Partners (ENSB) stock in Canada when it goes public
Everything we know about the Ensemble Health Partners IPO, plus information on how to buy in.
How to buy Fluence Energy (FLNC) stock in Canada when it goes public
Everything we know about the Fluence Energy IPO, plus information on how to buy in.
How to buy GlobalFoundries (GFS) stock in Canada when it goes public
Everything we know about the GlobalFoundries IPO, plus information on how to buy in.
How to buy LianBio (LIAN) stock in Canada when it goes public
Everything we know about the LianBio IPO, plus information on how to buy in.
How to buy Rent the Runway (RENT) stock in Canada when it goes public
Everything we know about the Rent the Runway IPO, plus information on how to buy in.
How to buy Solo Brands (DTC) stock in Canada when it goes public
Everything we know about the Solo Brands IPO, plus information on how to buy in.
How to buy Udemy (UDMY) stock in Canada when it goes public
Everything we know about the Udemy IPO, plus information on how to buy in.
How to buy Arteris (AIP) stock in Canada when it goes public
Everything we know about the Arteris IPO, plus information on how to buy in.
Ask an Expert
You must be logged in to post a comment.